{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:52:24Z","timestamp":1790275944191,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.intimp.2016.02.020","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T20:19:02Z","timestamp":1457036342000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-8830","authenticated-orcid":false,"given":"Soheil","family":"Tavakolpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2016.02.020_bb0005","doi-asserted-by":"crossref","first-page":"11439","DOI":"10.1073\/pnas.200360997","article-title":"Cloning of a type I cytokine receptor most related to the IL-2 receptor \u03b2 chain","volume":"97","author":"Ozaki","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.intimp.2016.02.020_bb0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/35040504","article-title":"Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function","volume":"408","author":"Parrish-Novak","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.02.020_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4049\/jimmunol.167.1.1","article-title":"Cutting edge: the common \u03b3-chain is an indispensable subunit of the IL-21 receptor complex","volume":"167","author":"Asao","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2014.12.047","article-title":"The role of IL-21 in immunity and cancer","volume":"358","author":"Davis","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2016.02.020_bb0025","doi-asserted-by":"crossref","first-page":"iii83","DOI":"10.1136\/ard.2008.098400","article-title":"Interleukin 21 as a target of intervention in autoimmune disease","volume":"67","author":"Ettinger","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2016.02.020_bb0030","article-title":"IL-21 acts as a promising therapeutic target in systemic lupus erythematosus by regulating plasma cell differentiation","author":"Deng","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0035","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s11033-010-0285-x","article-title":"Targeting interleukin-21 in rheumatoid arthritis","volume":"38","author":"Yuan","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2016.02.020_bb0040","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/eji.200838529","article-title":"IL-21 and autoimmune disease\u2014hypothesis and reality?","volume":"38","author":"Holmdahl","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0045","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/1346-8138.12697","article-title":"Immune cellular regulation on autoantibody production in pemphigus","volume":"42","author":"Pan","year":"2015","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","article-title":"A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab","volume":"14","author":"Ahmed","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2016.02.020_bb0055","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/exd.12229","article-title":"Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris","volume":"22","author":"Amber","year":"2013","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/08916934.2012.697593","article-title":"Cytokine networks in Pemphigus vulgaris: an integrated viewpoint","volume":"45","author":"Giordano","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2016.02.020_bb0065","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cyto.2015.09.017","article-title":"Interleukin 4 inhibition as a potential therapeutic in pemphigus","volume":"77","author":"Tavakolpour","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2016.02.020_bb0070","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1007\/s11033-010-0527-y","article-title":"Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus","volume":"38","author":"Li","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2016.02.020_bb0075","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.2174\/138920112802273281","article-title":"Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target","volume":"13","author":"Botti","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0080","article-title":"Interleukin-21: a new mediator of inflammation in systemic lupus erythematosus","volume":"2010","author":"Sarra","year":"2010","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.intimp.2016.02.020_bb0085","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1084\/jem.20020620","article-title":"Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon \u03b3-producing Th1 cells","volume":"196","author":"Wurster","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0090","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.4049\/jimmunol.177.6.3721","article-title":"IL-21 inhibits IFN-\u03b3 production in developing Th1 cells through the repression of Eomesodermin expression","volume":"177","author":"Suto","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.immuni.2012.09.007","article-title":"The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses","volume":"37","author":"Zhu","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2016.02.020_bb0100","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.4049\/jimmunol.169.7.3600","article-title":"IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response","volume":"169","author":"Strengell","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0105","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2006-05-021600","article-title":"IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo","volume":"109","author":"Fr\u00f6hlich","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2016.02.020_bb0110","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/eji.200838511","article-title":"IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo","volume":"38","author":"Sonderegger","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0115","doi-asserted-by":"crossref","first-page":"34605","DOI":"10.1074\/jbc.M705100200","article-title":"IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner","volume":"282","author":"Wei","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2016.02.020_bb0120","doi-asserted-by":"crossref","first-page":"478-","DOI":"10.1038\/sj.icb.7100152","article-title":"Autoimmunity: IL-21: a new player in Th17-cell differentiation","volume":"86","author":"Deenick","year":"2008","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature05969","article-title":"Essential autocrine regulation by IL-21 in the generation of inflammatory T cells","volume":"448","author":"Nurieva","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.02.020_bb0130","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdermsci.2008.09.008","article-title":"Lesional Th17 cells in pemphigus vulgaris and pemphigus foliaceus","volume":"53","author":"Arakawa","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.intimp.2016.02.020_bb0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2013.2177","article-title":"The imbalance of Th17 and regulatory T cells in pemphigus patients","volume":"23","author":"Xu","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0140","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2016.02.020_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri1807","article-title":"Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells","volume":"6","author":"Dong","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.coi.2006.03.017","article-title":"Expanding the effector CD4 T-cell repertoire: the Th17 lineage","volume":"18","author":"Harrington","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0155","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2016.02.020_bb0160","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0165","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/eji.201444726","article-title":"TGF-\u03b2 converts Th1 cells into Th17 cells through stimulation of Runx1 expression","volume":"45","author":"Liu","year":"2015","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0170","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4049\/jimmunol.178.2.732","article-title":"IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes","volume":"178","author":"Peluso","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0175","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2007-05-089375","article-title":"IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2016.02.020_bb0180","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.1201730","article-title":"IL-21 promotes CD8+ CTL activity via the transcription factor T-bet","volume":"190","author":"Sutherland","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0185","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/CJI.0b013e3181ad4071","article-title":"Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T lymphocytes","volume":"32","author":"Kaka","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2016.02.020_bb0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20041057","article-title":"Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function","volume":"201","author":"Zeng","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0195","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/icb.2012.14","article-title":"IL-27 induction of IL-21 from human CD8+ T cells induces granzyme B in an autocrine manner","volume":"90","author":"Mittal","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0200","first-page":"5304","article-title":"The modulatory capacity of interleukin-21 in the pathogenesis of autoimmune disease","volume":"13","author":"Vogelzang","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.intimp.2016.02.020_bb0205","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1077002","article-title":"A critical role for IL-21 in regulating immunoglobulin production","volume":"298","author":"Ozaki","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.intimp.2016.02.020_bb0210","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.4049\/jimmunol.179.9.5886","article-title":"Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell\u2013B cell collaboration","volume":"179","author":"Kuchen","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0215","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.4049\/jimmunol.173.9.5361","article-title":"Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6","volume":"173","author":"Ozaki","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0220","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.4049\/jimmunol.170.8.4111","article-title":"IL-21 induces the apoptosis of resting and activated primary B cells","volume":"170","author":"Mehta","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0225","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4049\/jimmunol.173.1.657","article-title":"Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis","volume":"173","author":"Jin","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0230","doi-asserted-by":"crossref","first-page":"7867","DOI":"10.4049\/jimmunol.175.12.7867","article-title":"IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells","volume":"175","author":"Ettinger","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0235","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1182\/blood-2002-04-1115","article-title":"Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line C\u03b5 transcription of IL-4-stimulated B cells","volume":"100","author":"Suto","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2016.02.020_bb0240","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood-2008-02-142745","article-title":"STAT3 is required for IL-21-induced secretion of IgE from human naive B cells","volume":"112","author":"Avery","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2016.02.020_bb0245","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cellimm.2005.01.001","article-title":"IL-21 effects on human IgE production in response to IL-4 or IL-13","volume":"231","author":"Wood","year":"2004","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0250","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7150\/ijbs.5996","article-title":"Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis","volume":"9","author":"Carbone","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2016.02.020_bb0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1084\/jem.167.1.183","article-title":"Differential regulation of IgG1 and IgE synthesis by interleukin 4","volume":"167","author":"Snapper","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-065X.1988.tb00741.x","article-title":"Regulation of IgG1 and IgE production by interleukin 4","volume":"102","author":"Snapper","year":"1988","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2016.02.020_bb0265","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1084\/jem.168.3.853","article-title":"Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures","volume":"168","author":"Lebman","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0270","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1365-2249.1990.tb08101.x","article-title":"The inductive effect of interleukin-4 on IgG4 and IgE synthesis in human peripheral blood lymphocytes","volume":"79","author":"Ishizaka","year":"1990","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0275","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.173.3.747","article-title":"Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones","volume":"173","author":"Gascan","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0280","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.4049\/jimmunol.181.3.1767","article-title":"IL-21-induced isotype switching to IgG and IgA by human naive B cells is differentially regulated by IL-4","volume":"181","author":"Avery","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0285","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nri3346","article-title":"B cells: IL-21 promotes B10 cell population expansion","volume":"12","author":"Leavy","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0290","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nature11501","article-title":"Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions","volume":"491","author":"Yoshizaki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2016.02.020_bb0295","first-page":"dxv026","article-title":"Regulatory B cells in human inflammatory and autoimmune diseases: from mouse models to clinical research","author":"Miyagaki","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/bjd.13192","article-title":"Impaired function of CD19+ CD24hiCD38hi regulatory B cells in patients with pemphigus","volume":"172","author":"Zhu","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0305","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN-\u03b3 production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0310","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2567.2007.02675.x","article-title":"Interleukin-21 differentially affects human natural killer cell subsets","volume":"122","author":"Wendt","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2016.02.020_bb0315","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2249.2008.03638.x","article-title":"Possible role of natural killer cells in pemphigus vulgaris \u2014 preliminary observations","volume":"152","author":"Stern","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0320","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.4049\/jimmunol.178.5.2827","article-title":"IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production","volume":"178","author":"Coquet","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0325","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/jid.2011.73","article-title":"IL-21 reduces immediate hypersensitivity reactions in mouse skin by suppressing mast cell activation or IgE production","volume":"131","author":"Tamagawa-Mineoka","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0330","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1182\/blood-2003-03-0669","article-title":"Interleukin-21 inhibits dendritic cell activation and maturation","volume":"102","author":"Brandt","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2016.02.020_bb0335","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1046\/j.1523-1747.2003.12603.x","article-title":"Interleukin-21 inhibits dendritic cell-mediated T cell activation and induction of contact hypersensitivity in vivo","volume":"121","author":"Brandt","year":"2003","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0340","doi-asserted-by":"crossref","first-page":"9595","DOI":"10.4238\/2015.August.14.22","article-title":"Association between IL-21 polymorphism and systemic lupus erythematosus: a meta-analysis","volume":"14","author":"Qi","year":"2014","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.intimp.2016.02.020_bb0345","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/art.24658","article-title":"A polymorphism within IL21R confers risk for systemic lupus erythematosus","volume":"60","author":"Webb","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2016.02.020_bb0350","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.humimm.2007.01.009","article-title":"Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes","volume":"68","author":"Asano","year":"2007","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0355","first-page":"7","article-title":"Investigation of IL-21 gene polymorphisms (rs2221903, rs2055979) in cases with multiple sclerosis of Azerbaijan, Northwest Iran","volume":"4","author":"Gharibi","year":"2015","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0360","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/gene.2009.105","article-title":"Association of the AFF3 gene and IL2\/IL21 gene region with juvenile idiopathic arthritis","volume":"11","author":"Hinks","year":"2010","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2016.02.020_bb0365","doi-asserted-by":"crossref","first-page":"99.36","DOI":"10.4049\/jimmunol.182.Supp.99.36","article-title":"IL-21 is increased in CD4+ T cells and serum from patients with systemic lupus erythematosus","volume":"182","author":"Nguyen","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0370","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar3474","article-title":"Doornbos-van der Meer B, Limburg PC, Kallenberg C, et al. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus","volume":"13","author":"Dolff","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2016.02.020_bb0375","doi-asserted-by":"crossref","first-page":"475","DOI":"10.33549\/physiolres.932701","article-title":"Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis","volume":"63","author":"Sglunda","year":"2014","journal-title":"Physiol. Res."},{"key":"10.1016\/j.intimp.2016.02.020_bb0380","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/art.22452","article-title":"Blockade of the interleukin-21\/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis","volume":"56","author":"Young","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2016.02.020_bb0385","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jecm.2014.02.010","article-title":"Interleukin-21 receptor might be a novel therapeutic target for the treatment of rheumatoid arthritis","volume":"6","author":"Seif","year":"2014","journal-title":"J. Exp. Clin. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0390","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2337\/db08-0882","article-title":"Interleukin-21 is required for the development of type 1 diabetes in NOD mice","volume":"58","author":"Sutherland","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2016.02.020_bb0395","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/db10-1157","article-title":"Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models","volume":"60","author":"McGuire","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2016.02.020_bb0400","doi-asserted-by":"crossref","first-page":"e68145","DOI":"10.1371\/journal.pone.0068145","article-title":"Follicular helper T cells (Tfh) and IL-21 involvement in the pathogenesis of bullous pemphigoid","volume":"8","author":"Li","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2016.02.020_bb0405","doi-asserted-by":"crossref","first-page":"119","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-BP180 NC16A IgG titres as an indicator of disease activity and outcome in Asian patients with bullous pemphigoid","volume":"44","author":"Cai","year":"2015","journal-title":"Ann. Acad. Med. Singap."},{"key":"10.1016\/j.intimp.2016.02.020_bb0410","doi-asserted-by":"crossref","DOI":"10.1038\/cr.2014.92","article-title":"Targeting Th17 cells in immune diseases","author":"Dong","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.intimp.2016.02.020_bb0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.3411","article-title":"Regulatory T cell proliferative potential is impaired in human autoimmune disease","volume":"20","author":"Carbone","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0420","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/08916938908997095","article-title":"Autoreactive cytotoxic T lymphocytes in pemphigus and pemphigoid","volume":"3","author":"Grando","year":"1989","journal-title":"Autoimmunity"},{"key":"10.1016\/j.intimp.2016.02.020_bb0425","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/TCRM.S3470","article-title":"Interleukin-6 inhibitors in the treatment of rheumatoid arthritis","volume":"4","author":"Hennigan","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.intimp.2016.02.020_bb0430","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1136\/annrheumdis-2013-205002","article-title":"IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab","volume":"73","author":"Tanaka","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2016.02.020_bb0435","series-title":"Therapeutic advances in musculoskeletal disease","article-title":"Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential","author":"Kellner","year":"2013"},{"key":"10.1016\/j.intimp.2016.02.020_bb0440","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/intimm\/dxs047","article-title":"Targeting TNF receptors in rheumatoid arthritis","volume":"24","author":"Bl\u00fcml","year":"2012","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0445","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor \u03b1 and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2016.02.020_bb0450","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/0961203313499417","article-title":"Targeted therapies in systemic lupus erythematosus","volume":"22","author":"Grech","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2016.02.020_bb0455","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40259-013-0015-8","article-title":"B-cell targeted therapies in systemic lupus erythematosus","volume":"27","author":"Harvey","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2016.02.020_bb0460","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clim.2012.11.001","article-title":"Cytokine inhibition as a strategy for treating systemic lupus erythematosus","volume":"148","author":"Clark","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0465","article-title":"Treatment of severe asthma: entering the era of targeted therapy","volume":"1-13","author":"van Buul","year":"2015","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2016.02.020_bb0470","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/MCP.0b013e3283413105","article-title":"Cytokine inhibition in severe asthma: current knowledge and future directions","volume":"17","author":"Corren","year":"2011","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.intimp.2016.02.020_bb0475","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.13664","article-title":"To (anti-) TNF or not (anti-) TNF? That is the question in pemphigus","volume":"172","author":"Sinha","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0480","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12327","article-title":"Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus","author":"Tavakolpour","year":"2016","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2016.02.020_bb0485","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjd.13350","article-title":"A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone","volume":"172","author":"Hall","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0490","first-page":"940","article-title":"Successful treatment of pemphigus vulgaris with etanercept in four patients","volume":"8","author":"Shetty","year":"2009","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0495","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2006.08.041","article-title":"Pemphigus foliaceus treated with etanercept","volume":"55","author":"Gubinelli","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2016.02.020_bb0500","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cyto.2014.11.002","article-title":"The dual nature of interleukin-10 in pemphigus vulgaris","volume":"73","author":"Cho","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2016.02.020_bb0505","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14656566.2014.854771","article-title":"Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib","volume":"15","author":"Yamaoka","year":"2014","journal-title":"Expert. Opin. Pharmacother."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916300558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916300558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T03:29:41Z","timestamp":1692242981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576916300558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":101,"alternative-id":["S1567576916300558"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2016.02.020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin 21 as a new possible player in pemphigus: Is it a suitable target?","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2016.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}